{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:45:31Z","timestamp":1784123131897,"version":"3.55.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work supported by the Startup Funding for Returned Scholars issued by the Department of Education in the Heilongjiang Province, China."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00074-7","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T08:58:13Z","timestamp":1746435493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures"],"prefix":"10.1038","volume":"15","author":[{"given":"Chuan-Feng","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"3","key":"74_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","volume":"33","author":"K Brigle","year":"2017","unstructured":"Brigle, K. & Rogers, B. Pathobiology and diagnosis of multiple myeloma. Semin. Oncol. Nurs. 33(3), 225\u2013236 (2017).","journal-title":"Semin. Oncol. Nurs."},{"key":"74_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","volume":"169","author":"MV Mateos","year":"2016","unstructured":"Mateos, M. V. & Landgren, O. MGUS and smoldering multiple myeloma: Diagnosis and epidemiology. Cancer Treat. Res. 169, 3\u201312 (2016).","journal-title":"Cancer Treat. Res."},{"key":"74_CR3","first-page":"211","volume":"56","author":"J Waldenstrom","year":"1960","unstructured":"Waldenstrom, J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 56, 211\u2013231 (1960).","journal-title":"Harvey Lect."},{"issue":"15","key":"74_CR4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23(15), 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"9983","key":"74_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig, C., Knop, S. & Bornhauser, M. Multiple myeloma. Lancet 385(9983), 2197\u20132208 (2015).","journal-title":"Lancet"},{"issue":"16","key":"74_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1056\/NEJM198010163031616","volume":"303","author":"JP Crowley","year":"1980","unstructured":"Crowley, J. P. Smoldering multiple myeloma. N. Engl. J. Med. 303(16), 941 (1980).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"74_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian, D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin. Oncol. 43(6), 676\u2013681 (2016).","journal-title":"Semin. Oncol."},{"issue":"6","key":"74_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.hoc.2007.08.009","volume":"21","author":"S Lentzsch","year":"2007","unstructured":"Lentzsch, S., Ehrlich, L. A. & Roodman, G. D. Pathophysiology of multiple myeloma bone disease. Hematol. Oncol. Clin. North Am. 21(6), 1035\u20131049 (2007).","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"74_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/hematology.2019000068","volume":"2019","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. Myeloma: Next generation immunotherapy. Hematol. Am. Soc. Hematol. Edu. Program 2019(1), 266\u2013272 (2019).","journal-title":"Hematol. Am. Soc. Hematol. Edu. Program"},{"issue":"14","key":"74_CR10","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Myeloma bone disease: from biology findings to treatment approaches. Blood 133(14), 1534\u20131539 (2019).","journal-title":"Blood"},{"key":"74_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan, A. M. & Rajkumar, S. V. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 5, e365 (2015).","journal-title":"Blood Cancer J."},{"issue":"9","key":"74_CR12","first-page":"846","volume":"17","author":"S Raza","year":"2017","unstructured":"Raza, S., Safyan, R. A. & Lentzsch, S. Immunomodulatory drugs (IMiDs) in multiple Myeloma. Curr. Cancer Drug Targets 17(9), 846\u2013857 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"4","key":"74_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/bjh.13870","volume":"172","author":"P Finsinger","year":"2016","unstructured":"Finsinger, P. et al. Clinical features and prognostic factors in solitary plasmacytoma. Br. J. Haematol. 172(4), 554\u2013560 (2016).","journal-title":"Br. J. Haematol."},{"issue":"8","key":"74_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt, J. M. et al. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27(8), 1482\u20131492 (2016).","journal-title":"Ann. Oncol."},{"issue":"4","key":"74_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.32","volume":"5","author":"T Dosani","year":"2015","unstructured":"Dosani, T. et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma[corrected] and their uses in immunotherapies. Blood Cancer J. 5(4), e306 (2015).","journal-title":"Blood Cancer J."},{"issue":"6","key":"74_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler, I. J. The pathogenesis of cancer metastasis: The \u201cseed and soil\u201d hypothesis revisited. Nat. Rev. Cancer 3(6), 453\u2013458 (2003).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"74_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.4202","volume":"22","author":"R Das","year":"2016","unstructured":"Das, R. et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 22(11), 1351\u20131357 (2016).","journal-title":"Nat. Med."},{"issue":"9","key":"74_CR18","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani, S. Z. et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial. Lancet Haematol. 6(9), e448\u2013e458 (2019).","journal-title":"Lancet Haematol."},{"key":"74_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier, S. et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 54, 100929 (2022).","journal-title":"Blood Rev."},{"issue":"5","key":"74_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s43018-020-0063-1","volume":"1","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. & Zhang, Z. Stepwise immune alterations in multiple myeloma progression. Nat. Cancer 1(5), 477\u2013479 (2020).","journal-title":"Nat. Cancer"},{"issue":"24","key":"74_CR21","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K., Smyth, M. J. & Martinet, L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136(24), 2731\u20132740 (2020).","journal-title":"Blood"},{"issue":"9","key":"74_CR22","first-page":"SP392","volume":"27","author":"ML Shaw","year":"2021","unstructured":"Shaw, M. L. The MMRF: Understanding and sharing the genomic landscape of multiple myeloma. Am. J. Manag. Care 27(9), SP392 (2021).","journal-title":"Am. J. Manag. Care"},{"key":"74_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab050","author":"M Settino","year":"2021","unstructured":"Settino, M. & Cannataro, M. MMRFBiolinks: An R-package for integrating and analyzing MMRF-CoMMpass data. Brief. Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab050 (2021).","journal-title":"Brief. Bioinform."},{"issue":"17","key":"74_CR24","doi-asserted-by":"publisher","first-page":"13366","DOI":"10.18632\/oncotarget.24351","volume":"9","author":"L Rao","year":"2018","unstructured":"Rao, L. et al. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(\u00ae) protein MP0250: A preclinical study. Oncotarget 9(17), 13366\u201313381 (2018).","journal-title":"Oncotarget"},{"issue":"8","key":"74_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1261\/rna.074922.120","volume":"26","author":"S Zhao","year":"2020","unstructured":"Zhao, S., Ye, Z. & Stanton, R. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA 26(8), 903\u2013909 (2020).","journal-title":"RNA"},{"issue":"11","key":"74_CR26","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper, R. et al. A gene expression signature for high-risk multiple myeloma. Leukemia 26(11), 2406\u20132413 (2012).","journal-title":"Leukemia"},{"issue":"12","key":"74_CR27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12), 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"74_CR28","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8017","volume":"7","author":"X Zhong","year":"2019","unstructured":"Zhong, X. et al. Cellular components in tumor microenvironment of neuroblastoma and the prognostic value. PeerJ 7, e8017 (2019).","journal-title":"PeerJ"},{"issue":"5","key":"74_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"74_CR30","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"issue":"1","key":"74_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12967-019-2126-6","volume":"17","author":"X Bao","year":"2019","unstructured":"Bao, X. et al. A novel epigenetic signature for overall survival prediction in patients with breast cancer. J. Transl. Med. 17(1), 380 (2019).","journal-title":"J. Transl. Med."},{"issue":"D1","key":"74_CR32","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M. et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44(D1), D457\u2013D462 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"74_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2), 337\u2013344 (2000).","journal-title":"Biometrics"},{"issue":"4","key":"74_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MOH.0000000000000049","volume":"21","author":"MR Green","year":"2014","unstructured":"Green, M. R. & Alizadeh, A. A. Common progenitor cells in mature B-cell malignancies: Implications for therapy. Curr. Opin. Hematol. 21(4), 333\u2013340 (2014).","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"74_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00223-016-0162-2","volume":"100","author":"MM McDonald","year":"2017","unstructured":"McDonald, M. M. et al. Adipose, bone, and myeloma: Contributions from the microenvironment. Calcif. Tissue Int. 100(5), 433\u2013448 (2017).","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"74_CR36","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","volume":"186","author":"TN Trotter","year":"2016","unstructured":"Trotter, T. N. et al. Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone. Am. J. Pathol. 186(11), 3054\u20133063 (2016).","journal-title":"Am. J. Pathol."},{"issue":"8","key":"74_CR37","doi-asserted-by":"publisher","first-page":"a031286","DOI":"10.1101\/cshperspect.a031286","volume":"8","author":"G Silvia Marino","year":"2018","unstructured":"Silvia Marino, G. & Roodman, D. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb. Perspect. Med. 8(8), a031286. https:\/\/doi.org\/10.1101\/cshperspect.a031286 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"6","key":"74_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/erm.11.44","volume":"11","author":"SY Kristinsson","year":"2011","unstructured":"Kristinsson, S. Y. et al. Bone disease in multiple myeloma and precursor disease: Novel diagnostic approaches and implications on clinical management. Expert Rev. Mol. Diagn. 11(6), 593\u2013603 (2011).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"5","key":"74_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41416-020-01200-0","volume":"124","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br. J. Cancer 124(5), 896\u2013900 (2021).","journal-title":"Br. J. Cancer"},{"key":"74_CR40","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2023.13","volume":"25","author":"J Parker","year":"2023","unstructured":"Parker, J. et al. Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia. Expert Rev. Mol. Med. 25, e16 (2023).","journal-title":"Expert Rev. Mol. Med."},{"issue":"1","key":"74_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12916-020-01806-4","volume":"18","author":"S Charmsaz","year":"2020","unstructured":"Charmsaz, S. et al. ADAM22\/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Med. 18(1), 349 (2020).","journal-title":"BMC Med."},{"issue":"3","key":"74_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbrc.2017.08.114","volume":"492","author":"Y Jin","year":"2017","unstructured":"Jin, Y. et al. GABRB2 plays an important role in the lymph node metastasis of papillary thyroid cancer. Biochem. Biophys. Res. Commun. 492(3), 323\u2013330 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"74_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188891","volume":"1878","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. S100A8 and S100A9 in cancer. Biochim. Biophys. Acta Rev. Cancer 1878(3), 188891 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"74_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2020.00721","volume":"11","author":"L Grosche","year":"2020","unstructured":"Grosche, L. et al. The CD83 molecule - An important immune checkpoint. Front. Immunol. 11, 721 (2020).","journal-title":"Front. Immunol."},{"issue":"2","key":"74_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4065\/84.2.114","volume":"84","author":"JA Lust","year":"2009","unstructured":"Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo. Clin. Proc. 84(2), 114\u2013122 (2009).","journal-title":"Mayo. Clin. Proc."},{"issue":"36","key":"74_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205629119","volume":"119","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. LAPTM5 mediates immature B cell apoptosis and B cell tolerance by regulating the WWP2-PTEN-AKT pathway. Proc. Natl. Acad. Sci. USA 119(36), e2205629119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"74_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. The role of CXCL family members in different diseases. Cell Death Discov. 9(1), 212 (2023).","journal-title":"Cell Death Discov."},{"issue":"11","key":"74_CR48","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 31(11), 1491\u20131505 (2020).","journal-title":"Ann. Oncol."},{"issue":"S1","key":"74_CR49","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.5045\/br.2021.2021032","volume":"56","author":"YS Choi","year":"2021","unstructured":"Choi, Y. S. Immuno-oncology for B-cell lymphomas. Blood Res. 56(S1), S70\u2013S74 (2021).","journal-title":"Blood Res."},{"issue":"1","key":"74_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/10245330310001652437","volume":"9","author":"H Murakami","year":"2004","unstructured":"Murakami, H., Ogawara, H. & Hiroshi, H. Th1\/Th2 cells in patients with multiple myeloma. Hematology 9(1), 41\u201345 (2004).","journal-title":"Hematology"},{"issue":"1","key":"74_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol. Oncol. 9(1), 116 (2016).","journal-title":"J Hematol. Oncol."},{"issue":"4","key":"74_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","volume":"5","author":"S Romagnani","year":"1999","unstructured":"Romagnani, S. Th1\/Th2 cells. Inflamm. Bowel. Dis. 5(4), 285\u2013294 (1999).","journal-title":"Inflamm. Bowel. Dis."},{"issue":"5","key":"74_CR53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/10428190290021579","volume":"43","author":"T Otsuki","year":"2002","unstructured":"Otsuki, T. et al. IL-10 in myeloma cells. Leuk. Lymphoma 43(5), 969\u2013974 (2002).","journal-title":"Leuk. Lymphoma"},{"issue":"20","key":"74_CR54","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1158\/0008-5472.CAN-08-2213","volume":"68","author":"S Hong","year":"2008","unstructured":"Hong, S. et al. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 68(20), 8456\u20138464 (2008).","journal-title":"Cancer Res."},{"issue":"26","key":"74_CR55","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala, R. H. et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115(26), 5385\u20135392 (2010).","journal-title":"Blood"},{"issue":"7","key":"74_CR56","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","volume":"21","author":"J Caers","year":"2007","unstructured":"Caers, J. et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia 21(7), 1580\u20131584 (2007).","journal-title":"Leukemia"},{"issue":"12","key":"74_CR57","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","volume":"55","author":"J Favaloro","year":"2014","unstructured":"Favaloro, J. et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk. Lymphoma 55(12), 2893\u20132900 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"74_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925266","volume":"13","author":"Z Yi","year":"2022","unstructured":"Yi, Z. et al. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. Front. Immunol. 13, 925266 (2022).","journal-title":"Front. Immunol."},{"issue":"1","key":"74_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41389-022-00380-z","volume":"11","author":"C Giallongo","year":"2022","unstructured":"Giallongo, C. et al. CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis 11(1), 6 (2022).","journal-title":"Oncogenesis"},{"issue":"11","key":"74_CR60","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. CXCL12-CXCR4\/CXCR7 axis in cancer: From mechanisms to clinical applications. Int. J. Biol. Sci. 19(11), 3341\u20133359 (2023).","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"74_CR61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.pan.2018.07.011","volume":"18","author":"NH Lee","year":"2018","unstructured":"Lee, N. H., Nikfarjam, M. & He, H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology 18(7), 705\u2013716 (2018).","journal-title":"Pancreatology"},{"key":"74_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","volume":"67","author":"X Xiang","year":"2022","unstructured":"Xiang, X. et al. Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. Cytokine Growth Factor Rev. 67, 35\u201348 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"74_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13402-020-00501-z","volume":"43","author":"H Bagheri","year":"2020","unstructured":"Bagheri, H. et al. CXCL-10: A new candidate for melanoma therapy?. Cell Oncol. (Dordr) 43(3), 353\u2013365 (2020).","journal-title":"Cell Oncol. (Dordr)"},{"issue":"6","key":"74_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128662","volume":"10","author":"T Watanabe","year":"2015","unstructured":"Watanabe, T. et al. Lipopolysaccharide-induced CXCL10 mRNA level and six stimulant-mRNA combinations in whole blood: Novel biomarkers for bortezomib responses obtained from a prospective multicenter trial for patients with multiple myeloma. PLoS ONE 10(6), e0128662 (2015).","journal-title":"PLoS ONE"},{"key":"74_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100253","volume":"17","author":"TR Ullah","year":"2019","unstructured":"Ullah, T. R. The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond. J. Bone. Oncol. 17, 100253 (2019).","journal-title":"J. Bone. Oncol."},{"issue":"5","key":"74_CR66","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/JLB.3A0918-345RR","volume":"105","author":"M Hernandez-Ruiz","year":"2019","unstructured":"Hernandez-Ruiz, M. et al. Cxcl17(-\/-) mice develop exacerbated disease in a T cell-dependent autoimmune model. J. Leukoc. Biol. 105(5), 1027\u20131039 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"74_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cytogfr.2020.04.004","volume":"53","author":"JA Choreno-Parra","year":"2020","unstructured":"Choreno-Parra, J. A. et al. The protective and pathogenic roles of CXCL17 in human health and disease: Potential in respiratory medicine. Cytokine Growth Factor Rev. 53, 53\u201362 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"74_CR68","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz, M. et al. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 14(1), 214 (2024).","journal-title":"Blood Cancer J."},{"issue":"5","key":"74_CR69","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/17474086.2018.1456331","volume":"11","author":"E Zamagni","year":"2018","unstructured":"Zamagni, E. et al. Anti-CD38 and anti-SLAMF7: The future of myeloma immunotherapy. Expert Rev. Hematol. 11(5), 423\u2013435 (2018).","journal-title":"Expert Rev. Hematol."},{"issue":"2","key":"74_CR70","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12282-025-01673-y","volume":"32","author":"MS Park","year":"2025","unstructured":"Park, M. S. et al. Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients. Breast Cancer 32(2), 416\u2013425. https:\/\/doi.org\/10.1007\/s12282-025-01673-y (2025).","journal-title":"Breast Cancer"},{"issue":"1","key":"74_CR71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12931-022-02226-z","volume":"23","author":"K Cao","year":"2022","unstructured":"Cao, K. et al. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma. Respir. Res. 23(1), 306 (2022).","journal-title":"Respir. Res."},{"issue":"11\u201312","key":"74_CR72","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41417-018-0070-x","volume":"26","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. Cancer Gene. Ther. 26(11\u201312), 347\u2013355 (2019).","journal-title":"Cancer Gene. Ther."},{"key":"74_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968165","volume":"13","author":"M Khan","year":"2022","unstructured":"Khan, M. et al. A novel necroptosis-related gene index for predicting prognosis and a cold tumor immune microenvironment in stomach adenocarcinoma. Front. Immunol. 13, 968165 (2022).","journal-title":"Front. Immunol."},{"key":"74_CR74","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bjh.18958","volume":"202","author":"SN Chen","year":"2023","unstructured":"Chen, S. N. et al. E2F2 modulates cell adhesion through the transcriptional regulation of PECAM1 in multiple myeloma. Br. J. Haematol. 202, 804 (2023).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"74_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002085","volume":"21","author":"M Gioia","year":"2023","unstructured":"Gioia, M. et al. Exo1 protects DNA nicks from ligation to promote crossover formation during meiosis. PLoS Biol. 21(4), e3002085 (2023).","journal-title":"PLoS Biol."},{"issue":"5","key":"74_CR76","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bbmt.2015.12.022","volume":"22","author":"K Shinozuka","year":"2016","unstructured":"Shinozuka, K. et al. Impact of polymorphic variations of gemcitabine metabolism, DNA damage repair, and drug-resistance genes on the effect of high-dose chemotherapy for relapsed or refractory lymphoid malignancies. Biol. Blood Marrow Transp. 22(5), 843\u2013849 (2016).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"10","key":"74_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048239","volume":"7","author":"T Berge","year":"2012","unstructured":"Berge, T. et al. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS ONE 7(10), e48239 (2012).","journal-title":"PLoS ONE"},{"issue":"7","key":"74_CR78","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/genes14071406","volume":"14","author":"Y Yunhan Wang","year":"2023","unstructured":"Yunhan Wang, Y. et al. High expression of CDca7 in the prognosis of glioma and its relationship with ferroptosis and immunity. Genes 14(7), 1406. https:\/\/doi.org\/10.3390\/genes14071406 (2023).","journal-title":"Genes"},{"issue":"1","key":"74_CR79","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe, C. T. & Mynott, R. L. Prognostic and predictive biomarker developments in multiple myeloma. J. Hematol. Oncol. 14(1), 151 (2021).","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"74_CR80","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023019758","volume":"142","author":"AM Poos","year":"2023","unstructured":"Poos, A. M. et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood 142(19), 1633\u20131646 (2023).","journal-title":"Blood"},{"issue":"11","key":"74_CR81","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura, F. et al. Genomic classification and individualized prognosis in multiple myeloma. J. Clin. Oncol. 42(11), 1229\u20131240 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"74_CR82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen, P., Zhang, J. & Barton, K. High-risk disease in newly diagnosed multiple myeloma: Beyond the R-ISS and IMWG definitions. Blood Cancer J. 12(5), 83 (2022).","journal-title":"Blood Cancer J."},{"issue":"29","key":"74_CR83","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino, M. et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J. Clin. Oncol. 40(29), 3406\u20133418 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"74_CR84","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s11427-021-2097-1","volume":"65","author":"L Zhong","year":"2022","unstructured":"Zhong, L. et al. Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution. Sci. China Life Sci. 65(9), 1811\u20131823 (2022).","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"74_CR85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12935-023-03007-4","volume":"23","author":"Z Yu","year":"2023","unstructured":"Yu, Z. et al. Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma. Cancer Cell Int. 23(1), 169 (2023).","journal-title":"Cancer Cell Int."},{"issue":"1","key":"74_CR86","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-023-01472-y","volume":"16","author":"F Sun","year":"2023","unstructured":"Sun, F. et al. A gene signature can predict risk of MGUS progressing to multiple myeloma. J. Hematol. Oncol. 16(1), 70 (2023).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"74_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10238-024-01499-6","volume":"24","author":"R Min","year":"2024","unstructured":"Min, R., Hu, Z. & Zhou, Y. Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: A novel risk model construction. Clin. Exp. Med. 24(1), 249 (2024).","journal-title":"Clin. Exp. Med."},{"issue":"8","key":"74_CR88","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","volume":"73","author":"C Guillerey","year":"2016","unstructured":"Guillerey, C. et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol. Life Sci. 73(8), 1569\u20131589 (2016).","journal-title":"Cell Mol. Life Sci."},{"issue":"5","key":"74_CR89","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13840","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo, C. Y. & Chng, W. J. Treatment horizon in multiple myeloma. Eur. J. Haematol. 109(5), 425\u2013440 (2022).","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"74_CR90","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41419-024-07038-1","volume":"15","author":"F Colombo","year":"2024","unstructured":"Colombo, F. et al. In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-\u03baB activation observed in vivo. Cell Death Dis. 15(10), 731 (2024).","journal-title":"Cell Death Dis."},{"issue":"4","key":"74_CR91","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41409-024-02505-x","volume":"60","author":"P Ahmadi","year":"2025","unstructured":"Ahmadi, P. et al. T cell redirection as a new standard of care for relapsed multiple myeloma: Impact on inpatient capacity, financial burden and infrastructural requirements in Germany. Bone Marrow Transplant. 60(4), 538\u2013540. https:\/\/doi.org\/10.1038\/s41409-024-02505-x (2025).","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"74_CR92","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3324\/haematol.2021.278342","volume":"107","author":"K Todoerti","year":"2022","unstructured":"Todoerti, K. et al. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica 107(4), 921\u2013932 (2022).","journal-title":"Haematologica"},{"issue":"21","key":"74_CR93","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1158\/0008-5472.CAN-20-1357","volume":"80","author":"N Manfrini","year":"2020","unstructured":"Manfrini, N. et al. FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy. Cancer Res. 80(21), 4693\u20134706 (2020).","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"74_CR94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S. et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132), 48\u201361 (2015).","journal-title":"Cell"},{"issue":"12","key":"74_CR95","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17(12), e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"issue":"6280","key":"74_CR96","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280), 1463\u20131469 (2016).","journal-title":"Science"},{"issue":"1","key":"74_CR97","doi-asserted-by":"publisher","first-page":"17653","DOI":"10.1038\/s41598-018-36367-3","volume":"8","author":"TY Choi","year":"2018","unstructured":"Choi, T. Y. et al. BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice. Sci. Rep. 8(1), 17653 (2018).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00074-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:03:17Z","timestamp":1746435797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00074-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No objections.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"15662"}}